Company research
AtaiBeckley Inc.
CIK 2081043Updated Sep 26, 2026
Securities
Historical securities (1)
ATAI · NASDAQ · equity · closed Sep 10, 2026Name history
atai Life Sciences Luxembourg S.A. · through Dec 31, 2025
ATAI price & chart
Historical security
This listing closed Sep 10, 2026. Live provider charts are shown only for current listings.
About the company
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 was granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has initiated Phase 3 activities; VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
In the news
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time ↗
Shareholder Alert: Ademi LLP investigates whether AtaiBeckley Inc. is obtaining a Fair Price for Public Shareholders ↗
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 292,723,000Source | 159,387,000Source |
| Property, Plant and Equipment, NetUSD | 2,166,000Source | 2,535,000Source |
| GoodwillUSD | 331,000Source | 331,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,851,000Source | 3,246,000Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 85,300,000Source | 17,505,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 667,000Source | 354,000Source |
| Assets, CurrentUSD | 275,684,000Source | 80,125,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 19,644,000Source | 7,795,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,846,000Source | 1,334,000Source |
| Other Assets, NoncurrentUSD | 1,110,000Source | 850,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 70,722,000Source | 42,833,000Source |
| Stockholders’ equity: | ||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 3,633,000Source | 18,785,000Source |
| Additional Paid in CapitalUSD | 1,599,421,000Source | 816,185,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,360,254,000Source | -700,207,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -20,926,000Source | -18,466,000Source |
| Stockholders' Equity Attributable to ParentUSD | 221,874,000Source | 116,297,000Source |
| Liabilities and EquityUSD | 292,723,000Source | 159,387,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 23,479,000Source | 24,951,000Source |
| Operating Lease, Liability, CurrentUSD | 271,000Source | 477,000Source |
| Accounts Payable, CurrentUSD | 4,906,000Source | 2,616,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,801,000Source | 732,000Source |
| Other Liabilities, NoncurrentUSD | 754,000Source | 2,695,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 127,000Source | 257,000Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 14,168,000Source | 9,847,000Source |
| Long-term DebtUSD | 0Source | 14,133,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 6,374,000Source |
| Partners' CapitalUSD | 222,001,000Source | 116,554,000Source |
| Restricted Cash and Investments, CurrentUSD | 0Source | 10,000,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -660,147,000Source | -150,049,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 1,012,000Source | 473,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 14,213,000Source | 25,490,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts PayableUSD | -1,695,000Source | -1,872,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -102,675,000Source | -82,437,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -109,127,000Source | 59,172,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 901,000Source | 6,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 269,481,000Source | 5,374,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 57,795,000Source | -17,529,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 85,300,000Source | 27,505,000Source |
| Supplemental disclosure of cash flow information: | ||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 793,000Source | 2,159,000Source |
| Income Taxes Paid, NetUSD | 589,000Source | — |
| Additional Financial Items | ||
| Amortization of Intangible AssetsUSD | 400,000Source | 200,000Source |
| DepreciationUSD | 600,000Source | 200,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 3,100,000Source | 3,800,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 1,908,000Source | -1,263,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 2,024,000Source | -1,078,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | -692,000Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 700,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | -408,000Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | -1,317,000Source | 0Source |
| General and Administrative ExpenseUSD | 65,088,000Source | 47,544,000Source |
| GoodwillUSD | 331,000Source | 331,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 33,000Source | 919,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | -2,000,000Source |
| Income Tax Expense (Benefit)USD | 298,000Source | -356,000Source |
| InterestExpenseNonoperatingUSD | 1,162,000Source | 3,124,000Source |
| Investment Income, InterestUSD | 1,478,000Source | 778,000Source |
| Net Income (Loss) Attributable to ParentUSD | -660,047,000Source | -149,269,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -100,000Source | -780,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -660,047,000Source | -149,269,000Source |
| Nonoperating Income (Expense)USD | -15,788,000Source | -45,714,000Source |
| Operating ExpensesUSD | 648,150,000Source | 102,999,000Source |
| Other Nonoperating Income (Expense)USD | -3,059,000Source | 5,514,000Source |
| Other Operating Income (Expense), NetUSD | -3,059,000Source | 5,514,000Source |
| Payments of Financing CostsUSD | 0Source | 161,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 0Source | 65,560,000Source |
| Proceeds from Stock Options ExercisedUSD | 10,437,000Source | 535,000Source |
| Restricted Cash and Investments, CurrentUSD | 0Source | 10,000,000Source |
| Restructuring CostsUSD | 2,860,000Source | 2,029,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 4,089,000Source | 308,000Source |
| Operating Income (Loss)USD | -644,061,000Source | -102,691,000Source |
| Other Nonoperating Income (Expense)USD | -3,059,000Source | 5,514,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -659,849,000Source | -148,405,000Source |
| Income Tax Expense (Benefit)USD | 298,000Source | -356,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -100,000Source | -780,000Source |
| Net Income (Loss) Attributable to ParentUSD | -660,047,000Source | -149,269,000Source |
| Earnings Per Share, BasicUSD per share | -2.91Source | -0.93Source |
| Earnings Per Share, DilutedUSD per share | -2.91Source | -0.93Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 226,532,786Source | 160,159,983Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 226,532,786Source | 160,159,983Source |
| Interest Expense (non-operating)USD | 1,162,000Source | 3,124,000Source |
| Additional Financial Items | ||
| Amortization of Intangible AssetsUSD | 400,000Source | 200,000Source |
| Current Income Tax Expense (Benefit)USD | 298,000Source | -356,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 3,100,000Source | 3,800,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 1,908,000Source | -1,263,000Source |
| General and Administrative ExpenseUSD | 65,088,000Source | 47,544,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | -148,405,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -64,645,000Source | -95,551,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | -2,000,000Source |
| Investment Income, InterestUSD | 1,478,000Source | 778,000Source |
| Labor and Related ExpenseUSD | 400,000Source | 500,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -660,047,000Source | -149,269,000Source |
| Nonoperating Income (Expense)USD | -15,788,000Source | -45,714,000Source |
| Operating ExpensesUSD | 648,150,000Source | 102,999,000Source |
| Other Operating Income (Expense), NetUSD | -3,059,000Source | 5,514,000Source |
| Research and Development ExpenseUSD | — | 900,000Source |
| Restructuring CostsUSD | 2,860,000Source | 2,029,000Source |
Offerings
Registration 333-290446
Filing attachments
ef20078103_ex99-1.htm · 8-K · 2026-07-16
EX-99.1 4 ef20078103_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 July 16, 2026 For Release: Immediately Refer to: Jessica Bardoulas; jessica.bardoulas@lilly.com; (Media) Michael Czapar; czapar_michael_c@lilly.com; (Investors) Jason Awe, PhD; Jason. Awe@ataibeckley.com (Investors) Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions AtaiBeckley’s lead program, BPL-003, is d…
Read attachment ↗ef20072731_ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 ef20072731_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 ───────────────────────────────────────────────────────────────────────────────────────────────────────── VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 ─────────────────────────────────────────────────────────────…
Read attachment ↗ef20066721_ex99-1.htm · 8-K · 2026-03-06
EX-99.1 2 ef20066721_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On June 2, 2025, atai Beckley N.V. (“atai”, f/k/a atai Life Sciences N.V.) entered into a share purchase agreement with Beckley Psytech Limited (“Beckley Psytech”) and certain selling shareholders of Beckley Psytech, pursuant to which atai agreed to acquire from the shareholders of Beckley Psytech, excluding atai (the “Sellers”), the entire issued share capit…
Read attachment ↗ef20066741_ex99-1.htm · 8-K · 2026-03-06
EX-99.1 2 ef20066741_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗ef20066741_ex99-2.htm · 8-K · 2026-03-06
EX-99.2 3 ef20066741_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Creating breakthroughs in mental health Investor Day March 6, 2026 The following disclaimer applies to this Presentation of AtaiBeckley (the “Company”). For the purposes of this disclaimer, “Presentation” means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting. Forward-Looking Statements This …
Read attachment ↗ef20066456_ex99-1.htm · 8-K · 2026-02-26
EX-99.1 2 ef20066456_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profile EMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at …
Read attachment ↗